Valuation: Alkermes plc

Market Cap 9.2B 8.06B 7.44B 6.87B 13.04B 879B 13.28B 89.16B 34.69B 431B 34.56B 33.8B 1,496B P/E 2026 *
-144x
P/E 2027 * 93.6x
Enterprise Value 10.17B 8.9B 8.22B 7.59B 14.4B 971B 14.67B 98.47B 38.32B 476B 38.17B 37.33B 1,653B EV / Sales 2026 *
5.62x
EV / Sales 2027 * 5.24x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day-1.68%
1 week+3.62%
Current month+3.62%
1 month+26.85%
3 months+64.42%
6 months+84.91%
Current year+94.03%
1 week 51.72
Extreme 51.72
55.67
1 month 43.03
Extreme 43.03
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 31/01/1991
Director of Finance/CFO 53 14/09/2025
Chief Tech/Sci/R&D Officer 58 29/05/2017
Director TitleAgeSince
Chairman 64 31/08/2011
Director/Board Member 74 25/05/2016
Director/Board Member 63 29/03/2018
Date Insider Type Main position Quantity % Market Cap.
07-05Sell

Compliance Officer

-2,034 0.0012%
06-30Fiscal year

Chief Technology Officer

19,000 0.0114%
06-11Sell

Director

-2,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-1.68%+3.62%+85.73%+81.69% 9.2B
-0.24%+4.98%+2.69%+9.14% 49.74B
-0.36%+1.33%+417.51%+619.10% 40.49B
-2.29%+5.93%+25.27%+59.26% 34.35B
-2.13%+5.47%+25.45%-6.01% 34.75B
-0.79%+2.02%+3.83%+36.42% 26.98B
+3.82%+3.92% - - 16.58B
-2.62%+0.45%+66.82%+125.87% 15.6B
-2.17%+6.52%+102.15%+102.15% 14.27B
-2.70%-2.19%+11.25%+18.19% 13.76B
Average -1.12%+4.13%+82.30%+116.20% 25.57B
Weighted average by Cap. -1.02%+4.40%+93.41%+136.97%

Financials

2026 *2027 *
Net sales 1.81B 1.58B 1.46B 1.35B 2.56B 173B 2.61B 17.53B 6.82B 84.77B 6.79B 6.65B 294B 1.89B 1.66B 1.53B 1.41B 2.68B 181B 2.73B 18.32B 7.13B 88.58B 7.1B 6.94B 307B
Net income -62.72M -54.93M -50.69M -46.84M -88.88M -5.99B -90.5M -608M -236M -2.94B -236M -230M -10.2B 107M 94.02M 86.76M 80.17M 152M 10.26B 155M 1.04B 405M 5.03B 403M 394M 17.45B
Net Debt 961M 842M 777M 718M 1.36B 91.84B 1.39B 9.31B 3.62B 45.03B 3.61B 3.53B 156B 702M 614M 567M 524M 994M 67.03B 1.01B 6.8B 2.64B 32.86B 2.63B 2.58B 114B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
08/07/26 US$54.29 -1.68% 1,705,989
07/07/26 US$55.22 +0.15% 1,719,310
06/07/26 US$55.14 +1.03% 1,747,218
02/07/26 US$54.58 +5.53% 1,653,919
01/07/26 US$51.72 -1.29% 1,638,365
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
54.29USD
Average target price
50.19USD
Spread / Average Target
-7.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock